Willemijn Hobo

3.0k total citations
50 papers, 2.2k citations indexed

About

Willemijn Hobo is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Willemijn Hobo has authored 50 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Immunology, 32 papers in Oncology and 9 papers in Hematology. Recurrent topics in Willemijn Hobo's work include Immune Cell Function and Interaction (29 papers), CAR-T cell therapy research (23 papers) and Immunotherapy and Immune Responses (21 papers). Willemijn Hobo is often cited by papers focused on Immune Cell Function and Interaction (29 papers), CAR-T cell therapy research (23 papers) and Immunotherapy and Immune Responses (21 papers). Willemijn Hobo collaborates with scholars based in Netherlands, United States and Germany. Willemijn Hobo's co-authors include Harry Dolstra, Nicolaas Schaap, Robbert van der Voort, Frans Maas, Anniek B. van der Waart, Joop H. Jansen, Hanny Fredrix, J.H. Frederik Falkenburg, Wieger J. Norde and Rob Woestenenk and has published in prestigious journals such as Nature Communications, Blood and The Journal of Immunology.

In The Last Decade

Willemijn Hobo

49 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Willemijn Hobo Netherlands	26	1.5k	1.3k	520	322	138	50	2.2k
Sébastien Anguille Belgium	29	1.7k 1.2×	1.5k 1.1×	873 1.7×	426 1.3×	151 1.1×	88	2.7k
Robbert van der Voort Netherlands	28	1.4k 0.9×	1.1k 0.8×	658 1.3×	281 0.9×	87 0.6×	43	2.4k
Maite Álvarez United States	25	1.5k 1.0×	1.0k 0.8×	357 0.7×	338 1.0×	54 0.4×	67	2.1k
Guitta Maki France	19	1.6k 1.1×	1.2k 0.9×	412 0.8×	308 1.0×	79 0.6×	24	2.3k
Ranjani Rajapaksa United States	17	1.3k 0.9×	807 0.6×	605 1.2×	333 1.0×	221 1.6×	23	1.9k
Jake Y. Henry United Kingdom	12	1.1k 0.8×	1.1k 0.9×	411 0.8×	384 1.2×	145 1.1×	18	1.7k
Christian M. Capitini United States	23	702 0.5×	670 0.5×	530 1.0×	182 0.6×	115 0.8×	87	1.7k
Jeanette Baker United States	26	2.3k 1.6×	1.2k 0.9×	333 0.6×	1.1k 3.4×	143 1.0×	65	3.1k
Tim Luetkens United States	23	718 0.5×	658 0.5×	469 0.9×	416 1.3×	102 0.7×	57	1.4k
Concetta Quintarelli Italy	27	1.0k 0.7×	1.4k 1.1×	628 1.2×	338 1.0×	62 0.4×	67	2.4k

Countries citing papers authored by Willemijn Hobo

Since Specialization

Citations

This map shows the geographic impact of Willemijn Hobo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willemijn Hobo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willemijn Hobo more than expected).

Fields of papers citing papers by Willemijn Hobo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willemijn Hobo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willemijn Hobo. The network helps show where Willemijn Hobo may publish in the future.

Co-authorship network of co-authors of Willemijn Hobo

This figure shows the co-authorship network connecting the top 25 collaborators of Willemijn Hobo. A scholar is included among the top collaborators of Willemijn Hobo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willemijn Hobo. Willemijn Hobo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rodríguez‐Fanjul, Vanessa, Willemijn Hobo, Anna L. de Goede, et al.. (2025). Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD/SCID/IL2Rgnull mice. Cellular and Molecular Life Sciences. 82(1). 210–210. 2 indexed citations

Evert, Janneke S. Hoogstad‐van, Paul K.J.D. de Jonge, Petra L.M. Zusterzeel, et al.. (2025). Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial. Gynecologic Oncology. 204. 91–99. 1 indexed citations

Brummelman, Jolanda, Dorette S. van Ingen Schenau, Mirjam H.M. Heemskerk, et al.. (2023). Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo. Cellular and Molecular Life Sciences. 80(10). 298–298. 2 indexed citations

Waart, Anniek B. van der, Willemijn Hobo, Jianming Wu, et al.. (2023). Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity. Cytotherapy. 26(3). 252–260. 6 indexed citations

Ho, Nataschja I., Maaike W.G. Looman, Esther D. Kers‐Rebel, et al.. (2023). Saponin-based adjuvants enhance antigen cross-presentation in human CD11c⁺ CD1c⁺ CD5⁻ CD163⁺ conventional type 2 dendritic cells. Journal for ImmunoTherapy of Cancer. 11(8). e007082–e007082. 11 indexed citations

Thordardottir, Soley, Anniek B. van der Waart, J.H. Frederik Falkenburg, et al.. (2021). Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer Immunology Immunotherapy. 70(11). 3167–3181. 16 indexed citations

Jonge, Paul K.J.D. de, Anniek B. van der Waart, Jolanda Brummelman, et al.. (2021). CD34 ⁺ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg ^null mice. OncoImmunology. 10(1). 1981049–1981049. 14 indexed citations

Evert, Janneke S. Hoogstad‐van, Alan J. Korman, Paul K.J.D. de Jonge, et al.. (2020). TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. OncoImmunology. 9(1). 1843247–1843247. 54 indexed citations

Waart, Anniek B. van der, Diana Campillo-Davó, Hanny Fredrix, et al.. (2020). PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. Bone Marrow Transplantation. 55(12). 2308–2318. 15 indexed citations

10.

Hobo, Willemijn, et al.. (2020). Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells. Cancer Immunology Immunotherapy. 69(11). 2259–2273. 3 indexed citations

11.

Guldevall, Karolin, Paul K.J.D. de Jonge, Janneke S. Hoogstad‐van Evert, et al.. (2020). IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer Immunology Immunotherapy. 70(5). 1305–1321. 33 indexed citations

12.

Hobo, Willemijn, et al.. (2019). Comprehensive Phenotyping of T Cells Using Flow Cytometry. Cytometry Part A. 95(6). 647–654. 137 indexed citations

13.

Heskamp, Sandra, Janneke D.M. Molkenboer‐Kuenen, Soley Thordardottir, et al.. (2018). PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. Cancer Immunology Research. 7(1). 150–161. 30 indexed citations

14.

Hobo, Willemijn, Yun Ji, Hanny Fredrix, et al.. (2018). Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8⁺ T cells for adoptive immunotherapy. OncoImmunology. 7(10). e1488565–e1488565. 45 indexed citations

15.

Roeven, Mieke W.H., Willemijn Hobo, Remco van Doorn, et al.. (2017). A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. Bone Marrow Transplantation. 52(10). 1378–1383. 23 indexed citations

16.

Thordardottir, Soley, Hanny Fredrix, Rob Woestenenk, et al.. (2016). CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. The Journal of Immunology. 197(7). 2715–2725. 40 indexed citations

17.

Waart, Anniek B. van der, Willemijn Hobo, & Harry Dolstra. (2015). Time toAkt. OncoImmunology. 4(5). e1003016–e1003016. 4 indexed citations

18.

Roeven, Mieke W.H., Willemijn Hobo, Robbert van der Voort, et al.. (2015). Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18. Journal of Immunotherapy. 38(4). 145–154. 40 indexed citations

19.

Dulos, John, Gregory J. Carven, Willemijn Hobo, et al.. (2012). PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer. Journal of Immunotherapy. 35(2). 169–178. 259 indexed citations

20.

Norde, Wieger J., Frans Maas, Willemijn Hobo, et al.. (2011). PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation. Cancer Research. 71(15). 5111–5122. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact